Parsing parasites' genomes. Genome sequencing may help shed new light on how worms--the parasitic, body-invading types--do their dastardly work. Researchers from Washington University's McDonnell Genome Institute, Britain's Wellcome Sanger Institute, and Edinburgh University conducted the wide-ranging study that examined the inner biology of parasites, and how it may affect the way that worms interact with the immune system. And that, in turn, could lead to more sophisticated drug development for dealing with the invaders. (Reuters)

FDA defends controversial opioid approval. Food and Drug Administration (FDA) Commissioner Scott Gottlieb issued a lengthy statement on Friday defending the agency's approval of a powerful new opioid drug that's considerably stronger than the already-powerful fentanyl, Dsuvia from AcelRx. Of note, Gottlieb points out the drug was developed in conjunction with the Department of Defense and is targeted toward a very specific segment of the population: "I believe that the unique aspects of Dsuvia, including those that make this drug a high priority for the Pentagon, differentiate this new formulation of sufentanil from other sufentanil products in a way that is consistent with population-based considerations for how it fits into the overall drug armamentarium. The FDA has made it a high priority to make sure our soldiers have access to treatments that meet the unique needs of the battlefield, including when intravenous administration is not possible for the treatment of acute pain related to battlefield wounds." (Fortune)

Sage inches toward post-partum drug approval. Sage Therapeutics' stock did a funny thing on Monday: It sank more than 8% on news that the FDA will almost certainly approve its pioneering post-partum depression drug, the first of its kind. The reason? The small sample size of clinical trials and the therapy's risk/benefit profile could sharply limit its market potential. Case in point: The treatment's expected approval could come with a requirement that patients have to receive extensive, monitored administration of the drug over a 72 hour period. (Fortune)

The problem with peer review. Aaron Carroll has a wonderful piece in the New York Times on the limits of peer reviewed medical research (a system which he still defends as the best possible choice amid a whole bunch of imperfect options). Here's one critique/suggestion for improvement that stood out to me: "For starters, more formal training might improve quality and speed. Given how hard it is to recruit good reviewers, journal editors could consider better incentives, such as paying reviewers for their time. The unpaid costs of peer review were estimated at 1.9 billion pounds (almost $3.5 billion) in 2008. Or journals could offer, without promise of acceptance, quicker turnaround for a reviewer's future papers. Academia might offer more formal recognition for review work as well." (New York Times)

Credit Card Chips Fail to Halt Fraud, Survey Says, by Jeff John Roberts

U.S. Companies Warn Tariffs and Tax Policy Could Make for a Bad 2019, by Hallie Detrick

Two to Tango: Parsing Trump's Argentine Dinner Date with Xi, by Clay Chandler

This Startup Wants to Bring 'Common Sense' to Self-Driving Cars, by Renae Reints

[ceo_attribution author="Produced by Sy Mukherjee" email="sayak.mukherjee@fortune.com" twitter="the_sy_guy"]
Find past coverage. Sign up for other Fortune newsletters.